Fetroja (cefiderocol) / Shionogi - LARVOL DELTA

Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease. (PubMed, Rev Esp Quimioter) - No abstract available

Journal • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

An in vitro comparative study of cefiderocol, siderophore-aztreonam and siderophore-daptomycin conjugates against select gram-negative bacteria. (PubMed, Bioorg Med Chem) - "Our in vitro studies demonstrated that siderophore conjugates exhibit comparable or superior antimicrobial activity to, with daptomycin conjugates notably retaining efficacy over extended periods. These findings suggest that conjugation with iron chelators that closely mimic natural siderophores can improve antibiotic delivery and activity, providing complementary options to existing therapies for multidrug-resistant Gram-negative infections."

Journal • Preclinical • Infectious Disease

Deciphering the genotypic profiles of Carbapenem-resistant Enterobacterales: A study from a tertiary care hospital in Bihar, India. (PubMed, New Microbes New Infect) - "Recommended therapies include Cefiderocol or Ceftazidime-avibactam plus Aztreonam. Continued molecular research and diagnostic enhancements remain critical."

Journal • Infectious Disease • Pneumonia

Multidrug-Resistant Organisms in Combat-Related Injuries: Insights from Iraq, Afghanistan, Ukraine, and Implications for Large-Scale Combat Operations. (PubMed, Mil Med) - "The MDRO burden in combat casualties is escalating in scale and severity, with direct implications for LSCO and PFC. Mitigation requires standardized antimicrobial protocols across Role 1 and Role 2 levels of care, centralized oversight by the Defense Health Agency, deployable rapid diagnostics, robust stewardship and infection-prevention programs, and resilient logistics-including drone-enabled medical resupply-to maintain antimicrobial effectiveness and operational readiness."

Journal • Infectious Disease • Pneumonia

Metallo-β-lactamase-producing Pseudomonas aeruginosa: epidemiology, diagnostic challenges and therapeutic strategies in the era of MDR/XDR resistance. (PubMed, Front Microbiol) - "Among treatment, cefiderocol represents the most evidence-supported option for MBL-producing strains. Aztreonam-based combinations offer an alternative treatment option, provided susceptibility is confirmed by synergy testing. Emerging antimicrobials (e.g., taniborbactam-, xeruborbactam-, and zidebactam-containing regimens) and novel strategies such as bacteriophage therapy are regarded as promising alternatives...MBL-producing P. aeruginosa requires an integrated, mechanism-based diagnostic and therapeutic strategy incorporating local epidemiology, rapid diagnostics and optimized antimicrobial selection. Ongoing development of novel agents and precision microbiology tools is expected to further refine clinical management."

Journal • Review • Infectious Disease

Global epidemiology of carbapenem-resistant Pseudomonas aeruginosa. (PubMed, JAC Antimicrob Resist) - "When traditional antipseudomonal agents lack activity against CRPA, novel β-lactam/β-lactamase inhibitor combinations may be effective treatment options, and cefiderocol may retain in vitro activity against MBL-producing CRPA. Continued epidemiologic monitoring and development of new antibiotics will be crucial to combatting the global threat of CRPA."

Journal • Review • Critical care • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice. (PubMed, Front Cell Infect Microbiol) - "This critical narrative Review integrates 27 pivotal-trial protocol identifiers included in a predefined evidence map, immune-phenotype-specific cohorts, contemporary guidance, pharmacokinetic/pharmacodynamic evidence, and treatment-emergent resistance reports for a bounded core set of newer agents first authorized in the United States or European Union between 2014 and 2025, including newer β-lactam/β-lactamase-inhibitor combinations, cefiderocol, sulbactam-durlobactam, aztreonam-avibactam, and selected non-β-lactams. The Review then synthesizes treatment by resistance mechanism and applies a host-pathogen-drug-context framework to empirical selection, diagnostics, exposure optimization, source control, de-escalation, relapse, and resistance. The resulting evidence map supports mechanism-active therapy while making the limits of transfer auditable and defining priorities for standardized phenotype reporting and pragmatic enrollment."

Journal • Review • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Neutropenia • Oncology • Pediatrics • Primary Immunodeficiency • Solid Organ Transplantation • Solid Tumor • Transplantation

Hypermutators Drive Cefiderocol Heteroresistance in Pseudomonas aeruginosa Cystic Fibrosis Isolates (NACFC 2026) - "Hypermutators were identified by the frequency of spontaneous resistant mutants selected on rifampicin. Hypermutators from CF patients are at high-risk for FDC hR and may be missed by routine susceptibility testing. Pairing FDC with dual ?-lactamase/PBP2 inhibitors is a promising strategy to overcome hR in these strains."

Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Respiratory Diseases

In vitro activity of zosurabalpin against a global set of carbapenem-resistant-A. baumannii clinical isolates. (PubMed, Antimicrob Agents Chemother) - "We compared zosurabalpin's activity with currently available antibiotics, including colistin, cefiderocol, sulbactam-durlobactam, as well as rifabutin. Zosurabalpin MICs in CRAB isolates were generally low, including metallo-β-lactamase-producing-CRAB. The low MICs show a high potential to overcome current treatment limitations; however, mutations in lptD may contribute to resistance emergence and should be further studied."

Journal • Preclinical • Infectious Disease

Escherichia coli with penicillin-binding protein 3 insertions: implications for newer β-lactam/β-lactamase inhibitor combinations. (PubMed, Antimicrob Agents Chemother) - "Newer β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, aztreonam/avibactam, and cefepime/taniborbactam) and cefiderocol with affinities for PBP3 show reduced activity against E. coli with YRIN and YRIK insertions...In contrast, agents targeting PBP2, such as cefepime/zidebactam and cefiderocol-xeruborbactam, retain potent in vitro activity and will likely be important for future treatment strategies...There is an urgent need for enhanced global surveillance, along with rapid diagnostic tools capable of identifying PBP3 insertions and associated high-risk clones among carbapenemase-producing E. coli. Future strategies should prioritize agents with activities against multiple essential PBPs to preserve β-lactam efficacy."

Journal • Review

In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. (PubMed, Antimicrob Agents Chemother) - "Cefiderocol failed to achieve stasis against a cefiderocol-resistant isolate. E219K impaired cefiderocol efficacy in vivo, supporting close monitoring of cefiderocol activity against isolates carrying this variant."

Journal • Preclinical • Infectious Disease

Molecular epidemiology and genomic characteristics of clinical Acinetobacter baumannii isolates from patients with hospital-acquired pneumonia in China, 2019-2020: a multicentre retrospective study. (PubMed, EBioMedicine) - "This study demonstrates the extremely high prevalence and clonal dominance of CRAB in Chinese patients with HAP, providing critical evidence for clinical treatment, antimicrobial stewardship, and targeted infection control."

Journal • Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases

Activity of cefiderocol against carbapenem nonsusceptible Gram-negative isolates from skin and soft tissue infections in US and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020-2024) (IDWeek 2026) - No abstract available

Gram negative • Infectious Disease

Activity of Cefiderocol Against Carbapenem-Resistant Pseudomonas aeruginosa Encountered In Each of the Different United States Census Bureau Divisions (IDWeek 2026) - No abstract available

Infectious Disease

Differential Effects of Ceftazidime/Avibactam plus Aztreonam, Cefiderocol, and Levofloxacin in Mono- versus Co-Culture of Pseudomonas aeruginosa and Stenotrophomonas maltophilia (IDWeek 2026) - No abstract available

Infectious Disease

Impact of Iron on Bacteriophage-Cefiderocol Synergy Against Biofilm Producing MDR/XDR Pseudomonas aeruginosa (IDWeek 2026) - No abstract available

Infectious Disease

Cefiderocol-Xeruborbactam Antimicrobial Susceptibility Testing Does Not Require Iron-Depleted Media (IDWeek 2026) - No abstract available

Infectious Disease

Reproducibility of Cefiderocol-Xeruborbactam MIC Determinations in Cation Adjusted Mueller Hinton Broth and Iron Depleted CAMHB using Two Reading Endpoints (IDWeek 2026) - No abstract available

Infectious Disease

Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Pseudomonas aeruginosa, Including Molecularly Characterized Isolates Recovered Globally in 2024 (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Global Acinetobacter baumannii-calcoaceticus species complex Isolates (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Enterobacterales, Including Molecularly Characterized Isolates Recovered Globally in 2024 (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

Bactericidal Activity of Cefiderocol/Xeruborbactam in a Murine Urinary Tract Infection Model (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Is three a crowd: evaluating cefiderocol dual vs. triple therapy against multidrug-resistant Stenotrophomonas maltophilia strains (IDWeek 2026) - No abstract available

Infectious Disease

Activity of Cefiderocol against Metallo-Beta-Lactamase Carrying Pseudomonas aeruginosa of the SENTRY Antimicrobial Surveillance Program (2020 – 2024) (IDWeek 2026) - No abstract available

Infectious Disease

Inhibiting Multiple Penicillin-Binding-Proteins with Novel β-lactam Combinations is a Clinically Viable Therapeutic Strategy to Overcome Aztreonam-Avibactam and Cefiderocol Resistance in Metallo-β-lactamase Producing Enterobacterales (IDWeek 2026) - No abstract available

Clinical • Infectious Disease